The role of MyosinX in BMPs promotion of SMAD 1/5 in osteoclast formation and fun
The role of MyosinX in BMPs promotion of SMAD 1/5 in osteoclast formation and fun
批准号:
8782667
负责人:
Amy Tasca
金额:
$6.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-27 至 2016-05-26
关键词:
AntibodiesBMP2 geneBone DiseasesBone MarrowBone MatrixBone Morphogenetic ProteinsBone RegenerationBone ResorptionBone TransplantationBone remodelingCathepsinsCell surfaceCellsClinicalDataDevelopmentDiseaseEndothelial CellsExcisionFractureGene ExpressionGenerationsHealedIn VitroKnock-outLeadLentivirus VectorMAP Kinase GeneMalignant NeoplasmsMediatingMolecularMononuclearMusMyosin ATPaseOpen FracturesOrthopedicsOsteoblastsOsteoclastsOsteogenesisOsteoporosisPathogenesisPathway interactionsPatternPeriodontal DiseasesPhenotypePreventionProceduresProcessPublishingResearchReverse Transcriptase Polymerase Chain ReactionRheumatoid ArthritisRoleSignal PathwaySignal TransductionStagingTRANCE proteinTestingTherapeuticTimeTraumaTreatment outcomeWestern BlottingWorkbisphosphonatebonebone healingbone lossbone morphogenetic protein 9bone morphogenetic protein receptorscathepsin Kcraniofacialcytokinegastrulationhealingimprovedin vivoinnovationinsightknock-downmouse modelnew therapeutic targetnovelnovel therapeuticsosteoclastogenesisoverexpressionprotein expressionpublic health relevanceresearch studysealtherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Excessive osteoclast activity can lead to pathological bone resorption, which is a serious consequence of many clinical diseases including, osteoporosis, metastastic bone disease and periodontal disease. Therefore, current therapies such as bisphosphonates and denosumab (anti-RANKL antibody) have focused on inhibiting osteoclast function. Furthermore, it is becoming clear that osteoclasts are required for overall bone remodeling, and therapeutic elimination may cause more harm than good. Therefore, to improve treatment outcomes, understanding the cellular signaling networks involved in bone remodeling process is important to identifying more effective therapeutic targets. BMPs, which are currently used therapeutically to promote bone healing and regeneration, have been shown by us and others to act synergistically with RANKL, the main cytokine responsible in activating osteoclasts, to enhance osteoclastogenesis. BMPs can signal through both noncanonical MAPK signaling and canonical Smad 1/5 signaling. Previous data from our lab has shown that phospho-SMAD 1/5 expression increases in osteoclasts at the time of fusion of mononuclear precursors into multinucleated osteoclasts. I have generated mice that are conditionally deleted for Smad 1 and 5 in osteoclasts using the Cathepsin-Cre mice to test the hypothesis that Smad 1/5 expression is necessary for osteoclast fusion and activity. Secondly, I have generated preliminary data demonstrating that the expression of myosin X, an unconventional myosin responsible for regulating the sealing zone patterning in osteoclasts, increases with BMP2 stimulation of osteoclasts and is a downstream target of Smad 1/5. At the completion of my proposed experiments I expect to better understand osteoclast differentiation, particularly during osteoclast fusion and thereby uncover potential novel therapeutic targets that can be used to inhibit osteoclast function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of MyosinX in BMPs promotion of SMAD 1/5 in osteoclast formation and fun
-
批准号:8849297
-
项目类别:
-
资助金额:$6.95万
-
财政年份:2014
-
负责人:Amy Tasca
-
依托单位:
海外基金